



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,909	10/05/2005	Marc Preaudat	LOM-0047	7128
23599 7590 08/05/2010 MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400 ARLINGTON, VA 22201				
EXAMINER SEHN, BIN				
ART UNIT		PAPER NUMBER		
1657				
NOTIFICATION DATE		DELIVERY MODE		
08/05/2010		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

docketing@mwzb.com

1
2 RECORD OF ORAL HEARING
3 UNITED STATES PATENT AND TRADEMARK OFFICE
4

5 BEFORE THE BOARD OF PATENT APPEALS
6 AND INTERFERENCES
7
8

9 Ex parte MARC PREAUDAT, CHIKASHI TOKUDA,
10 and LAURENCE JACQUEMART
11

12 Appeal 2009-012075
13 Application 10/522,909
14 Technology Center 1600
15
16

17
18 Oral Hearing Held: June 24, 2010
19
20

21 Before ERIC B. GRIMES, DEMETRA J. MILLS, and
22 MELANIE L. McCOLLUM, Administrative Patent Judges.
23
24

25 On Behalf of the Appellants:
26
27

28 Sagun KC, Esq.
29 Diana Hamlet-Cox, Esq.
30 Millen, White, Zelano & Branigan, P.C.
31 2200 Clarendon Boulevard, Suite 1400
32 Arlington, Virginia 22201
33 (703) 812-5316
34
35
36
37

1 The above-entitled matter came on for hearing on Thursday,
2 June 25, 2010, commencing at 9:00 a.m., at the U.S. Patent and Trademark
3 Office, 600 Dulany Street, 9th Floor, Hearing Room A, Alexandria,
4 Virginia, before Jan M. Jablonsky, court reporter.

5 THE USHER: Appeal Number 2009-012075, Mr. KC.

6 JUDGE GRIMES: Good morning, Mr. KC.

7 MR. KC: Good morning, Your Honor.

8 JUDGE GRIMES: Before you get started, if you would not
9 mind introducing your guest for the record, and if you have a business card,
10 the court reporter would appreciate it.

11 MR. KC: I did not bring a business card along with me.

12 JUDGE GRIMES: And if you wouldn't mind introducing your
13 guest for the record?

14 MR. KC: Sure. My name is Sagun KC. I'm with Millen,
15 White, Zelano & Branigan, and with me is Diana Hamlet-Cox. She is an
16 attorney at Millen, White, Zelano & Branigan, as well. And we're here on
17 behalf of our client, Mark Preaudat, et al. And the assignee of record, which
18 is CIS Bio International.

19 This is Appeal Number 2009-012075 in relation to certain
20 claims of this application which have been rejected under 103(a) as allegedly
21 being obvious in view of two references. The first reference is by Bazin et
22 al. in Spectrochimica Acta. And the second reference is United States Patent
23 to Nicolson, et al.

24 The claims of this application are directed to a method for
25 measuring endoglycosidase activity comprising employing a substrate,
26 which is cleaved by endoglycosidase. The steps are you contact a sample

1 containing the endoglycosidase with the substrate and the substrate has two
2 moieties attached to it: a donor moiety and an acceptor moiety; and you're
3 measuring the amount of intact substrate by monitoring the reduction in the
4 energy between the transfer of energy between the donor and the acceptor
5 molecules.

6 So if I may read the claim, it's a method for determining
7 endoglycosidase enzyme activity in a sample comprising bringing a
8 substrate which can be cleaved by said endoglycosidase into contact with
9 said sample and measuring the change in the amount of intact substrate. The
10 decrease in the amount of substrate being representative of the
11 endoglycosidase activity, and the substrate is directly or indirectly bound
12 with a donor compound and an acceptor compound, and the amount of intact
13 substrate is measured by measuring the signal emitted by the acceptor
14 compound.

15 The signal is usually because of a change of a transfer via a
16 close proximity between the donor and the acceptor molecules. The
17 Examiner relies on two references, as I mentioned earlier. The first primary
18 reference is by Bazin et al., and Bazin is concerned with the methods of
19 measuring protease enzyme activity. Proteases as we know are different
20 from endoglycosidase in terms of the substrates that they act on.

21 Proteases by definition act on proteins. Endoglycosidases act
22 on glycosidic linkages or sugar molecules. So the macromolecular structure
23 is different. On one end we have sugar molecules, and the other end we
24 have protein molecules. And in Bazin et al, they basically describe
25 fluorescence, resonance, energy transfer, or the threat process between one
26 during a compound. In this case it's a cryptate which has a rare earth metal

1 bound to it which can transfer energy to an accepted molecule, and in this
2 case it's an allophycocyanin and you're basically measuring a cleavage of the
3 protein by the action of a protease. The secondary reference that the
4 Examiner --

5 JUDGE GRIMES: The assay that's used in the Bazin reference,
6 that is one that meets the limitation in your claim. Correct? You've got the
7 signal emitted by the acceptor compound?

8 MR. KC: Yes, yes. That's correct, Your Honor.

9 JUDGE GRIMES: It's just the different substrate being
10 included?

11 MR. KC: Right. Right. It's a different substrate being included
12 and the secondary reference that the Examiner relies on is a method for
13 measuring endoglycosidase activity using a substrate Heparin Sulfate in this
14 case, which is cleaved by endoglycosidase. But the method relies on
15 measurement of fluorescence. There is no energy transfer process going on
16 between any of these moieties that are recited in our claims, and the method
17 employed by the secondary reference, Nicolson, relies on chromatographic
18 separation or resolution of the moiety that's cleaved through the action of
19 endoglycosidase.

20 So the Applicant's position in this case is that a combination of
21 Bazin and Nicolson fail to teach each and every element of the claimed
22 process. Also, there are certain secondary considerations that I wish to
23 mention here .

24 JUDGE GRIMES: Before you get into the secondary
25 considerations, why would it not be obvious to apply the fret assay from
26 Bazin to the substrate that's used in Nicolson?

MR. KC: Okay. The answer is in Bazin they use a peptide moiety that is cleaved, but is attached on one end. It's attached to a donor compound. On the second end it's attached to an acceptor compound. The peptide structure in comparison to Heparin sulfate, which is a substrate, one of the substantive examples of a substrate used in that application is very simple in that if you look at the amino acid sequence you can derivitize the N terminus or the C terminus. Okay.

So, basically, what the N terminus is derivitized with an acceptor of a donor compound, the C terminus is derivitized with an acceptor compound. So there is only a certain number of possibilities, possible structures that can be made for this process. In our case it's a sugar moiety; and, if you look at the simplest structure with is a heparin sulfate structure, it contains glycosamineglycan and that's glycosaminine. So the two compounds have at least six possible structural positions that you can derivitize. That's one part.

JUDGE GRIMES: Are you saying you wouldn't be able to limit the donor accept the fluorescence donor to one end and the fluorescence acceptor to the other end.

MR. KC: Yes, there are two considerations. One is that the enzyme, the donor and acceptor molecules have to be in sufficient proximity to allow energy transfer between the two moieties. And the secondary consideration is that well, you need sufficient proximity, but it cannot be in such proximity that the enzyme that acts on it is directly hindered, if I may. So those are the two considerations that you need to take into account.

And, unfortunately, the primary reference since it does not disclose any sugar molecules whatsoever, there's a broad disclosure of how

1 this technique can be applied for protein producing actions for binding to
2 RNA polymerases, study of those macromolecules, but does not teach or
3 suggest any sugar containing compounds. And that is the fundamental
4 difference between the present claim of the invention and the primary
5 reference.

6 The secondary reference does not rectify any of the limitations,
7 because as I discussed earlier it is using a simplistic chromatographic
8 separation and does not allow or does not each or suggest the resonance,
9 energy transfer between that. So it does not teach or suggest any of the
10 active method steps that I recited in the claims.

11 JUDGE GRIMES: You alluded to some secondary
12 considerations?

13 MR. KC: Yeah. Secondary considerations as I mentioned
14 earlier, Your Honor, you can look at the structure of the simplest molecule,
15 the substantive molecule, heparin sulfate. It is a polysaccharide that has
16 repeat chains of N-acetylglucosamine linked to D-glucuronic acid. So you
17 can have five possible secondary modifications. One is the epimerization of
18 one of the carbons to yield 20 different secondary structures.

19 The second is you can have sulfano moieties attached to the
20 hydroxyl groups off the carbon atoms in the sugar so that there is a different
21 secondary structure. So if you have a disaccharide owing to these five
22 possible permutations it leads to 32 different combinations. So a heparin
23 solvent molecule just containing two sugar residues would theoretically have
24 in a chain up to a million possible structures. So the structure and
25 complexity of the substrate in question is more diverse, more variable than
26 the substrates that I described by the cited prior art references.

1 That's my first point, and in order to support that position, we've
2 submitted this reference by Codee, which raises Applicant's position that the
3 heparin sulfate molecule is highly complex. It has different micro
4 heterogeneous secondary structures, and the resulting effect is that it is
5 virtually impossible to obtain specific heparin sulfate from natural sources.
6 And, lastly, I also wanted to mention is that one skilled in the art would have
7 appreciated the difference between the assays in question, which is
8 heparinase compared to the prior art teachings of protease assays and would
9 have instantly recognized that a protease assay is insufficient or does not
10 cater towards measurement of endoglycosidase activity.

11 JUDGE MCCOLLUM: Can you point me to any place in the
12 specification that might give me some guidance as to what the inventors had
13 to do to overcome the complexity issue? Like what did they have to do
14 differently? Does the specification talk about anything that they had to do
15 differently to make this work with this different substrate rather than the
16 peptide?

17 MR. KC: Right. If I remember correctly there's another
18 discussion with respect to measurement of heparinase activity and the
19 existing technologies that rely on chromatographic gelatin preparesus and
20 the like, but as far as the peptide substrates are concerned, I don't know if
21 there is explicit guidance in the specification, so. I mean in order to read my
22 position the prior art teachings have heparin sulfate tethered to a substrate
23 and you're measuring the lysed moiety of the lysed sugar residue in heparin
24 sulfate by chromatographic volution or gelatin preparesus so that you can
25 see a side migration. But it does not teach or suggest a sensitive assay
26 technique which can be using a Heitwood format for example and does not

1 require separation of the lysed moiety through a FRET-based analytical
2 technique.

3 JUDGE MILLS: Isn't it well-known to those of ordinary skill
4 in the art the substrates on which endoglycosidases act and we have a
5 teaching in the Bazin reference saying that the distance for energy efficient
6 transfer between molecules using the fret assay in the one to seven nanomole
7 range?

8 MR. KC: Correct.

9 JUDGE MILLS: Don't we have general teachings that would
10 guide one of ordinary skill in the art here?

11 MR. KC: Right. If I may, is that nanomole or nanometers? I
12 believe that this sense --

13 JUDGE GRIMES: Nanometer, yes. Maybe it's nanometer, yes.

14 MR. KC: Yes, you are absolutely right. The distance is, the
15 fret assay is based on really, real close proximity between the donor and the
16 accepted compounds. If you're using a peptide fib in a peptide format, let's
17 say you have a secondary structure prediction that allows you to tether these
18 donor and accepted compounds so that you would have energy transferred
19 between them. So its more predictable secondary structure so that you can
20 engineer, you know.

21 We had these donor and acceptor molecules designed so that
22 you can have the fret transfer. In our case in the sugar molecule, it's more
23 level, if I may. The second structure is not as rigid, so there's more difficulty
24 of predicting where the donor and the acceptor compounds reside.

25 JUDGE GRIMES: Do you have anything else to add?

26 MR. KC: I think that's it, Your Honor.

1 The hearing was concluded at 9:20 a.m.

2

3

4

5

6

7

8